Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
May 11th 2017

Pembrolizumab Plus Chemotherapy Approved for Metastatic Nonsquamous NSCLC

Surabhi Dangi-Garimella, PhD
Tumor response rate and progression-free survival were the benchmarks that helped pembrolizumab (Keytruda) gain accelerated approval as first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), in combination with chemotherapy.
Site Logo
May 11th 2017

Survival Inequalities in Childhood Leukemia Remain Large Worldwide, Despite Progress

Laura Joszt, MA
While global inequalities for survival of childhood leukemia have narrowed, the gap remains wide for acute lymphoblastic leukemia and acute myeloid leukemia, according to a study published in The Lancet Haematology. In some countries, the 5-year survival rate is nearly twice as high as in others for children diagnosed in 2005-2009.
Site Logo
May 10th 2017

USPSTF: Do Not Screen for Thyroid Cancer in Asymptomatic Individuals

Surabhi Dangi-Garimella, PhD
The US Preventive Services Task Force (USPSTF) has provided a D recommendation (discourages the use of service) for thyroid cancer screening in asymptomatic individuals.
The Future of Healthcare in the United States
May 10th 2017

The Future of Healthcare in the United States

How Will an ACA Repeal Affect Healthcare?
May 10th 2017

How Will an ACA Repeal Affect Healthcare?

The Politics of Healthcare Reform
May 10th 2017

The Politics of Healthcare Reform

Navigating Eligibility and Access Issues When Diagnosed
May 10th 2017

Navigating Eligibility and Access Issues When Diagnosed

The Balancing Act of Cost vs Access to Care
May 10th 2017

The Balancing Act of Cost vs Access to Care

Role of Health Plans in Medicaid Expansion
May 10th 2017

Role of Health Plans in Medicaid Expansion

ACA, Medicaid Expansion, and Cancer Care
May 10th 2017

ACA, Medicaid Expansion, and Cancer Care

ACA: Effect on Patients With Chronic Conditions
May 10th 2017

ACA: Effect on Patients With Chronic Conditions

Influence of Value Frameworks in Clinical Practice
May 10th 2017

Influence of Value Frameworks in Clinical Practice

Using Reimbursement Models to Overcome Oncology Care Gaps
May 10th 2017

Using Reimbursement Models to Overcome Oncology Care Gaps

Developing Appropriate Quality Measures in Oncology
May 10th 2017

Developing Appropriate Quality Measures in Oncology

Capturing Meaningful Measures in Cancer
May 10th 2017

Capturing Meaningful Measures in Cancer

Realizing Patient Goals in Cancer Care
May 10th 2017

Realizing Patient Goals in Cancer Care

Keeping Oncology Care Patient-Centered
May 10th 2017

Keeping Oncology Care Patient-Centered

Standardization of Biopsy Testing and Interpreting Data
May 10th 2017

Standardization of Biopsy Testing and Interpreting Data

Genomic Testing for Trial Participation and Access
May 10th 2017

Genomic Testing for Trial Participation and Access

Engaging Patients in Oncology Trials Is a Team Effort
May 10th 2017

Engaging Patients in Oncology Trials Is a Team Effort

What Will Patients Gain From the TAPUR Study?
May 10th 2017

What Will Patients Gain From the TAPUR Study?

Drug Price Arguments Have No Easy Answer
May 10th 2017

Drug Price Arguments Have No Easy Answer

Empowering Stakeholders with Innovative Trial Designs
May 10th 2017

Empowering Stakeholders with Innovative Trial Designs

Center of Excellence: Streamlining Drug Approvals
May 10th 2017

Center of Excellence: Streamlining Drug Approvals

FDA Center of Excellence and the Drug Approval Process
May 10th 2017

FDA Center of Excellence and the Drug Approval Process

Drug Price Negotiation by CMS
May 10th 2017

Drug Price Negotiation by CMS

Improving the Drug Approval Process to Reduce Drug Costs
May 10th 2017

Improving the Drug Approval Process to Reduce Drug Costs

Off-Label Communications to Inform Formulary Management
May 10th 2017

Off-Label Communications to Inform Formulary Management

Considerations With Off-Label Communication
May 10th 2017

Considerations With Off-Label Communication

Evidence From Drug Manufacturers and Patient Access
May 10th 2017

Evidence From Drug Manufacturers and Patient Access

<1
...
757677787980818283
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo